NCT06129409View on ClinicalTrials.gov

Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions
Cardiovascular Diseases
Interventions
DRUG

NT-0796

Orally administered capsules

Trial Locations (2)

33147

Investigative Site, Miami

78744

Investigative Site, Austin

All Listed Sponsors
lead

NodThera Limited

INDUSTRY

NCT06129409 - Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease | Biotech Hunter | Biotech Hunter